Summary: Centessa Pharmaceuticals announced that preclinical data from a non-human primate study of ORX142, an orexin receptor 2 (OX2R) agonist designed to address excessive daytime sleepiness (EDS) in various neurological, neurodegenerative, and psychiatric disorders, will be presented at the European Sleep Research Society Congress in September. The study demonstrated that low doses of ORX142 successfully promoted wakefulness in a highly predictive preclinical model, highlighting its potential as a therapeutic option for EDS.
Key Takeaways:
- Promising Preclinical Results: ORX142, a selective OX2R agonist, has shown effectiveness in promoting wakefulness at low doses in non-human primates, indicating its potential as a treatment for excessive daytime sleepiness.
- Upcoming Presentation: The detailed preclinical data will be presented at the European Sleep Research Society Congress, providing further insights into the drug’s efficacy and potential applications.
- Therapeutic Potential: ORX142 is part of a broader pipeline aimed at treating sleep-wake disorders and related conditions, with its promising preclinical performance suggesting it could alleviate EDS in select neurological and psychiatric disorders.
Centessa Pharmaceuticals plc announced that preclinical data from a non-human primate study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late-breaking poster presentation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) being held Sept 24-27, 2024, in Seville, Spain.
The poster presentation will feature preclinical data demonstrating that low doses of ORX142 promoted wakefulness in non-human primates in a highly predictive and translational model.
“ORX142 is the second drug candidate from our growing pipeline of potentially best-in-class OX2R agonists that has shown significant activity in promoting wakefulness at very low doses in highly predictive and translational preclinical models,” says Saurabh Saha, MD, PhD, chief executive officer of Centessa, in a release. “We believe these non-human primate data are compelling as they demonstrate the potential for ORX142, a highly potent and novel OX2R agonist, to alleviate excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders with no significant loss of orexin.”
Details of the poster presentation are as follows:
- Title: ORX142, an Oral, Highly Potent, and Selective Orexin Receptor 2 Agonist, Promotes Wakefulness in Non-Human Primates
- Poster number: P5073
- Authors: Sarah Wurts Black, Tod Steinfeld, Karl Gibson, Emiliangelo Ratti, David Grainger, Mario Alberto Accardi, and Deborah S. Hartman
- Poster Presentation: Thursday, Sept 26, at 12-13:30 and 17:30-18:45 (local time)
The abstracts are expected to be published approximately two weeks prior to the start of the conference.
Centessa’s Orexin Agonist Program
Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Low levels of orexin result in EDS and poor regulation of rapid eye movement (REM) sleep and, in narcolepsy type 1 (NT1), cataplexy and other symptoms.
Centessa is developing a pipeline of OX2R agonists intended to be orally administered for sleep-wake disorders, including NT1, narcolepsy type 2, and idiopathic hypersomnia, with therapeutic potential to alleviate EDS in select neurological, neurodegenerative, and psychiatric conditions.
The company’s lead asset, ORX750, is in a phase 1 clinical study. ORX750 and ORX142 have not been approved by the US Food and Drug Administration or any other regulatory authority. ORX142 is currently in Investigational New Drug-enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness.
ID 149837485 © Shutter2u | Dreamstime.com
Leave a Reply